A Randomized, Evaluator-Blinded, Phase 3 Study to Compare the Safety and Efficacy of PTK 0796 With Linezolid in the Treatment of Adults With Complicated Skin and Skin Structure Infection

Trial Profile

A Randomized, Evaluator-Blinded, Phase 3 Study to Compare the Safety and Efficacy of PTK 0796 With Linezolid in the Treatment of Adults With Complicated Skin and Skin Structure Infection

Discontinued
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2016

At a glance

  • Drugs Omadacycline (Primary) ; Omadacycline (Primary) ; Linezolid; Linezolid; Moxifloxacin; Moxifloxacin
  • Indications Bacterial infections; Skin and soft tissue infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Paratek Pharmaceuticals
  • Most Recent Events

    • 12 Apr 2016 Results of a pooled analysis (n=377) from this and other phase II trial (see profile 59200)presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases
    • 11 Apr 2016 According to a Paratek Pharmaceuticals media release, results of pooled analysis (n=377) from this and other phase II trial (see profile 59200) were presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).
    • 11 Apr 2016 Results of pooled analysis (n=377) from this and other phase II trial (see profile 59200) published in the Paratek Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top